Your browser doesn't support javascript.
loading
Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis.
Abastabar, Mahdi; Haghani, Iman; Shokohi, Tahereh; Hedayati, Mohammad Taghi; Aghili, Seyed Reza; Jedi, Ali; Dadashi, Sulmaz; Shabanzadeh, Shafigheh; Hosseini, Tahereh; Aslani, Narges; Meis, Jacques F; Badali, Hamid.
Afiliación
  • Abastabar M; Invasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Haghani I; Invasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Shokohi T; Invasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Hedayati MT; Invasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Aghili SR; Invasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Jedi A; Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
  • Dadashi S; Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
  • Shabanzadeh S; Invasive Fungi Research Center (IFRC), School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Hosseini T; Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
  • Aslani N; Department of Medical Parasitology and Mycology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
  • Meis JF; Centre of Expertise in Mycology Radboud University Medical Centre/Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
  • Badali H; Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
Antimicrob Agents Chemother ; 62(12)2018 12.
Article en En | MEDLINE | ID: mdl-30224524
The in vitro activity of tavaborole, an FDA-approved antifungal drug, was compared to that of four antifungal agents against 170 clinical fungal isolates originating from patients with onychomycosis. Tavaborole had low activity against all isolates compared to itraconazole, terbinafine, and fluconazole, the principal choices for treatment of onychomycosis. Thus, it appears that tavaborole is not a candidate for the treatment of onychomycosis due to Candida species, Aspergillus species, and dermatophytes.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Levaduras / Compuestos de Boro / Onicomicosis / Compuestos Bicíclicos Heterocíclicos con Puentes / Hongos / Antifúngicos Límite: Humans Idioma: En Revista: Antimicrob Agents Chemother Año: 2018 Tipo del documento: Article País de afiliación: Irán
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Levaduras / Compuestos de Boro / Onicomicosis / Compuestos Bicíclicos Heterocíclicos con Puentes / Hongos / Antifúngicos Límite: Humans Idioma: En Revista: Antimicrob Agents Chemother Año: 2018 Tipo del documento: Article País de afiliación: Irán